Some of these agents are tumour necrosis factor targets and are licenced for immune-related diseases, such as rheumatoid arthritis (Infliximab51) while others such as Ustekinumab target IL12A and are licenced for several diseases (psoriasis52, psoriatic arthritis53 and Crohn’s disease54), and are being repurposed for other immune diseases such as systemic lupus erythematosus55. The gene discussed is IL12A; the disease is immune system disorder.